Impact of SARS-COV2 infection on the clinical outcomes in patients with lung cancer

e20572 Background: The outbreak of 2019 Novel coronavirus disease (COVID-19) has led to various deleterious outcomes in cancer patients. Those with lung cancer would be more susceptible to increased morbidity and mortality. We aimed to study the outcomes of COVID infection in patients with lung cancer. Methods: Healthcare Cost and Utilization Project-Nationwide Inpatient Sample database-2020 was queried to identify all admissions with COVID in patients with and without lung cancer. The groups were compared for socio-demographic differences, medical comorbidities, inpatient mortality, length of stay (LOS), and total hospital charges (THC). Secondary outcomes included a diagnosis of thrombocytopenia (TCP), Acute Respiratory Failure (ARF), sepsis, anemia, pancytopenia and shock. Statistics were performed using t-test, univariate and multinomial logistic regression. Results: A total 4,625 COVID admissions occurred in patients with lung cancer. Among them 71% (N = 3,288) were white, 17% (N = 805) were African American (AA) and 6.7% (N = 310) were Hispanic (HISP). Lung cancer patients had higher rates of smoking heart failure, CKD, CAD, COPD and anemia (p < 0.01) and lower rates of DM and obesity (p < 0.01). Lung cancer patients were more likely to have Medicare and less likely to have private insurance and were older (mean age 64.7 vs 71.9, p < 0.01). On multivariate regression, after adjusting for confounders those with lung cancer had higher odds of all-cause mortality (aOR 1.41; 95% CI 1.18-1.70 ,p = < 0.001). Among lung cancer patients, mean LOS was lower by 1 day (95% CI -1.4 to -0.4, p < 0.001) and THC was also lower (-$16,672; 95% CI -22950 to -10393, p < 0.001). Among the secondary outcomes, lung cancer patients had higher rates of pancytopenia (7.46% vs 1.59%, p < 0.001), neutropenia (3.46% vs 0.68%, p < 0.001) and venous thromboembolism (8.97% vs 4.29%, p = 0.006). Conclusions: COVID-19 infection led to increased mortality in lung cancer patients compared to those without lung cancer. This explains the overwhelming impact the pandemic left on lung cancer patients. The LOS and THC was decreased for lung cancer patients which may be explained by early death compared to non-lung cancer cohort. This study highlights the importance of decreasing the risk factors for COVID infection among lung cancer patients, including encouraging vaccination.